•• Complete epithelial recovery was achieved by 67% of subjects receiving NEXAGON, as opposed to 27% receiving Vehicle alone
•• NEXAGON was well-tolerated demonstrating a safety profile similar to vehicle
•• Amber plans to initiate the NEXPEDE-1 Phase 2/3 clinical trial in subjects with PCED of various etiologies in Q1 2023 ••

The BioShift Pass-Through Germicidal UV Chamber is proven to efficiently decrease the possibility of a PED viral outbreak